CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Guerbet SA is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Guerbet SA
15 rue des Vanesses, Zone Paris Nord II
Phone: +33 145915000p:+33 145915000 VILLEPINTE, 93420  France Ticker: GBTGBT
Business Summary
Guerbet SA is a France-based pharmaceutical group specialized in the manufacture and marketing of medical imaging contrast agents destined for diagnostic purposes. It produces medical imaging contrast products for x-ray imaging, magnetic resonance imaging (MRI), ultrasound imaging and for nuclear medicine. The contrast agents are used in the diagnosis of cardio-vascular, inflammatory and neuro-degenerative disorders. The Company’s portfolio of products comprises brands, such as Xenetix, Hexabrix, Optiray, Oxilan, Telebrix, Lipiodol, Dotarem, Endorem, Artirem, Lumirem, and Lipiodol, among others. Guerbet SA is also active in the fine chemicals industry through its Simafex subsidiary. The Company operates through its subsidiaries, including Simafex, Medex, SCI KALB, Guerbet LLC, Guerbet Asie Pacifique and Guerbet GmbH, among others.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023Yes---Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
5122 Drugs, drug proprietaries, and druggists' sundries
3845 Electromedical and electrotherapeutic apparatus
3841 Surgical and medical instruments and apparatus

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Executive Committee, Chief Executive Officer DavidHale 54 1/1/2020
Independent Chairman of the Board DidierIzabel 67 5/26/2023 5/23/2014
Chief Financial Officer, Senior Vice President - IT and Business Development and Licensing, Member JeromeEstampes 1/1/2024 1/1/2019
12 additional Officers and Directors records available in full report.

Business Names
Business Name
0ELV
4G8
A. Martins & Fernandes Sarl
44 additional Business Names available in full report.

General Information
Number of Employees: 2,920 (As of 12/31/2023)
Outstanding Shares: 12,622,444 (As of 12/31/2023)
Shareholders: 3,400
Stock Exchange: EPA
Fax Number: +33 145915199


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 20, 2024